1Riichdesehel G, Dalhoff A. The moxifloxaein against legioneiia in vitro activity of species and The effects of medium on susceptibility test results. Jatimicrob Chemother, 1999,43 (supplB) :25 - 29.
2Stass H, Dalhoff A, Kubitza D, et al. Pharmacokinetics, safety, and to lerability of ascending single doses of moxifloxacin, a new 8 - methoxy guinolone, administered to healthy subjects, Antimicrob Agents themother, 1998,42 : 2060.
3Mblondeau J. The role of PK/PD paramelers to auoid selection and increase of resistance. Mutant prevention concentraion. Journal of Chemoterapy,2004,16 : 1-4.
2Niederman MS,Mandell LA,Anzueto A,et al.Guidelines for the management of adults with community-acquired pneumonia:diagnosis,assessment of severity,antimicrobial therapy,and prevention.Am J Respir Crit Care Med,2001,163:1730-1754
3Dunbar LM,Wunderink RG,Habib MP,et al.High-dose,short-course levofloxacin for community-acquired pneumonia:a new treatment paradigm.Clin Infect Dis,2003,7:752-760
4Finch R,Schurmann D,Collins O,et al.Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment.Antimicrob Agents Chemother,2002,46,1746-1754
5Faich GA,Morganroth J,Whitehouse AB,et al.Clinical experience with moxifloxacin in patients with respiratory tract infections.Ann Pharmacother,2004,38:749-754
